Hit enter to search or ESC to close
Immuneering Corporation
  • ABOUT
    • Our Approach
    • Team
    • In The News
  • PLATFORM
  • PIPELINE
  • FOR INVESTORS
  • PUBLICATIONS
  • CONTACT
    • Inquiries
    • Locations
    • Join Our Team
  • ABOUT
    • Our Approach
    • Team
    • In The News
  • PLATFORM
  • PIPELINE
  • FOR INVESTORS
  • PUBLICATIONS
  • CONTACT
    • Inquiries
    • Locations
    • Join Our Team
All Posts By

immun-ops2020

immun-ops2020 In Publications

Identifying transcriptomic mechanisms of gemcitabine resistance pathways in pancreatic cancer.

Although pancreatic cancer is increasing in incidence, therapeutic options remain limited. Treatment with gemcitabine or a gemcitabine combination therapy is most common, although current combination therapies are challenged by toxicity….

Read More
immun-ops2020 In Publications

Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor

Abstract Laquinimod is an oral drug currently being evaluated for the treatment of relapsing, remitting, and primary progressive multiple sclerosis and Huntington’s disease. Laquinimod exerts beneficial activities on both the…

Read More
immun-ops2020 In Publications

Pridopidine activates neuroprotective pathways impaired in Huntington Disease

Pridopidine has demonstrated improvement in Huntington Disease (HD) motor symptoms as measured by secondary endpoints in clinical trials. Originally described as a dopamine stabilizer, this mechanism is insufficient to explain…

Read More
immun-ops2020 In Publications

Abstract 789: Leveraging transcriptomic and genomic data to better select models for preclinical oncology therapeutic development to identify cell lines most similar to patient tumors

Cancer cell lines represent the front line of new compound testing, and results from these experiments often decide which compounds go on for further testing. Genomic context plays a critical…

Read More
immun-ops2020 In Publications

Similarities and differences in properties of glatiramer acetate (Copaxone®, Teva) versus polimunol (Synthon) using standard and emerging technologies: P11190

Background and aims: Copaxone ® is a non-biological complex drug (NBCD) for the treatment of multiple sclerosis. Recently, differently manufactured follow-on glatiramoid drug products (FOGAs) purported to be equivalent to…

Read More
immun-ops2020 In Publications

BIOLOGICAL MARKERS FOR IDENTIFYING IBRUTINIB RESISTANCE IN PATIENTS HAVING MANTLE CELL LYMPHOMA AND METHODS OF USING THE SAME

Disclosed herein are methods of predicting a likelihood of responsiveness to treatment with ibrutinib in a patient having mantle cell lymphoma and methods of treating a patient having mantle cell…

Read More
immun-ops2020 In Publications

Leveraging transcriptomic and genomic data to better select models for preclinical oncology therapeutic development to identify cell lines most similar to patient tumors

Cancer cell lines represent the front line of new compound testing, and results from these experiments often decide which compounds go on for further testing. Genomic context plays a critical…

Read More
immun-ops2020 In Publications

Leveraging public genomic data to accelerate oncology therapeutic development in pancreatic cancer.

Pancreatic cancer has an estimated survival rate of only 5-6% (Siegel et al. 2015). The difficulty in early detection methods compounded by clinical trial failures precipitates the need for innovative…

Read More
immun-ops2020 In Publications

Serum Proteomic Analysis of Multiple Myeloma Subjects Treated with Daratumumab Monotherapy

Daratumumab (DARA) is a human IgG1κ monoclonal antibody that binds with high affinity to a unique epitope on CD38. DARA monotherapy has shown promising activity in relapsed and/or refractory multiple…

Read More
immun-ops2020 In Publications

Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition

Glatiramer acetate (Copaxone®; GA) is a non-biological complex drug for multiple sclerosis. GA modulated thousands of genes in genome-wide expression studies conducted in THP-1 cells and mouse splenocytes. Comparing GA…

Read More
Previous 1 … 6 7 8 9 10 Next
Immuneering logo
  • ABOUT
  • PLATFORM
  • PIPELINE
  • PUBLICATIONS
  • FOR INVESTORS
  • CONTACT
  • Terms of Use
  • Privacy Policy

© 2025 Immuneering Corporation.